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Abstract A novel serine protease (PHBSP) was purified from
human plasma by two chromatographic steps with a final yield of
1.6 mg/l plasma. The protease consists of two disulfide-bridged
chains of about 50 and 30 kDa with the light chain containing the
active site of the enzyme. NH2-terminal sequence analysis
revealed identity to the deduced amino acid sequence of
HGFA-like mRNA. The activity of PHBSP is strongly
dependent on Ca2+ ions and is efficiently inhibited by K2-
antiplasmin and aprotinin. Possible functions of PHBSP in the
hemostatic system are discussed.
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1. Introduction
A large number of proteolytic enzymes circulates in blood
as zymogens and is speci¢cally activated by limited proteolysis
upon a variety of physiological events. Best known are the
proteases involved in coagulation, ¢brinolysis and comple-
ment activation. Another group of plasma proteins (about
10% of total plasma proteins) belongs to the large group of
protease inhibitors, most of them are serine protease inhibi-
tors (serpins) which play a central role in the regulation of
coagulation and ¢brinolysis. In order to study single steps in
the coagulation system, clotting factors have to be separated
from other plasma proteins, especially the very abundant se-
rum albumin, immunoglobulins and serpins. A well-estab-
lished protocol for the enrichment of vitamin K-dependent
coagulation factors includes the cryoprecipitation of fresh
plasma and the subsequent binding of cryo-supernatant pro-
teins to an anion exchange chromatography matrix followed
by elution of proteins with increasing salt concentrations [1,2].
During this type of puri¢cation we observed an amidolytic
activity in the high salt column regeneration wash towards a
thrombin-sensitive chromogenic substrate. Since hirudin did
not inhibit this activity, the substrate cleavage was considered
not to be caused by thrombin but by another protease which
is generated during the puri¢cation procedure. Hirudin-insen-
sitive amidolytic activities towards thrombin-selective chro-
mogenic substrates have previously been described to be
present in some therapeutically used clotting factor concen-
trates [3,4]. As the enzyme responsible for the chromogenic
activity had not yet been identi¢ed, we were interested to
clarify the identity of the protease.
Here we describe the puri¢cation of this novel serine pro-
tease from human plasma, which we call plasma hyaluronan
binding serine protease (PHBSP) and present ¢rst character-
istics of this enzyme. Possible physiological functions of
PHBSP are discussed.
2. Materials and methods
2.1. Materials
Materials were obtained from the following sources: Aprotinin-Eu-
pergit from Fluka (Buchs, Switzerland); chromogenic substrates of
the S series from Chromogenix (Mo«lndal, Sweden); chromogenic sub-
strates of the Pefachrome series from Pentapharm (Basel, Switzerland)
(cf. Table 1); DEAE Sephadex A50 from Pharmacia (Freiburg, Ger-
many); monoclonal antibodies, extravidin-peroxidase, 3,3P-diamino-
benzidine tetrahydrochloride (DAB), 7-hydroxy-7-O-(p-guanidino-
benzoyl)-4-methylcumarin (HBMC), 3,3P,5,5P-tetramethylbenzidine
(TMB), K2-antiplasmin, and trypsin from Sigma (Deisenhofen, Ger-
many); anti-mouse IgG-peroxidase from BioRad (Mu«nchen, Ger-
many); biotinylated D-Phe-Pro-Arg-chloromethylketone (PPACK),
K1-proteinase inhibitor, and C1-esterase inhibitor from Calbiochem
(Bad Soden, Germany); aprotinin from Boehringer (Mannheim, Ger-
many). Recombinant hirudin was prepared according to [5].
2.2. Puri¢cation of plasma hyaluronan binding protease (PHBSP)
Puri¢cation was performed at 4‡C. One l frozen plasma was thawed
overnight and centrifuged (30 min at 22 000Ug) in order to remove
the cryoprecipitate. After addition of DEAE Sephadex A 50 (1.5 g of
the dry gel matrix pre-swollen in 10 mM tri-sodium citrate, 125 mM
NaCl) and stirring of the suspension for 60 min, the gel was ¢lled into
a column and washed with at least two column volumes of washing
bu¡er. Bound proteins were stepwise eluted with bu¡er E1 (10 mM
tri-sodium citrate, 0.5 M NaCl) and bu¡er E2 (10 mM tri-sodium
citrate, 2 M NaCl).
Fractions containing amidolytic activity were pooled and precipi-
tated by addition of ammonium sulfate (66% of saturation). The
precipitate was dissolved in 50 mM Tris, 0.5 M NaCl, pH 8.0 and
ammonium sulfate was removed by gel ¢ltration. This solution was
applied to an Aprotinin-Eupergit a⁄nity column (4 U PHBSP/ml gel,
substrate S2765, see below). The matrix was washed with ¢ve column
volumes of each, equilibration bu¡er and 20 mM MES, pH 6.0, and
the bound protein was eluted with 100 mM sodium acetate, 0.2 M
NaCl, pH 4.0. Fractions containing amidolytic activity were pooled,
adjusted to pH 5.5 with 2 M Tris-base and stored in small aliquots in
liquid nitrogen.
2.3. Amidolytic assays
Enzyme activity was determined in amidolytic assays using various
chromogenic substrates. Assays were performed in microplates at
37‡C in 25 mM Tris-HCl, pH 8.2, containing 75 mM NaCl, 5 mM
CaCl2 and either 0.1% BSA or 0.05% Tween-20 in a total volume of
0.1 ml. Substrates were used at a ¢nal concentration of 1 mM. En-
zyme activities are expressed as U, which is de¢ned as the activity
which cleaves 1 Wmole substrate per minute. Inhibition experiments
were performed under the same bu¡er and temperature conditions.
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Kinetic constants of the interaction between PHBSP and aprotinin
were determined according to the theory of tight binding inhibition
by non-linear regression analysis [6,7]. The dependence of PHBSP
activity from divalent cations was tested in 50 mM Tris-HCl, pH
8.4, 100 mM NaCl, 0.2% BSA.
2.4. ELISA
Fractions of the DEAE eluate were tested for the presence of the
coagulation factors IX and X by ELISA using mouse monoclonal
antibodies, anti-mouse IgG-POD and TMB as substrate.
2.5. Protein concentration
Total protein content was determined by measuring the absorbance
at 280 nm. The molar extinction coe⁄cient of PHBSP at 280 nm was
calculated from the deduced amino acid sequence of the mature pro-
tein according to Gill and von Hippel [8] and amounts to 93 220 M31.
2.6. Gel electrophoresis and Western blot
Proteins were separated on SDS polyacrylamide gels according to
Laemmli [9]. For Western blotting the gel was preincubated for 20
min in transfer bu¡er (25 mM Tris, 192 mM glycine, 20% methanol,
pH 8.3), followed by transfer to a PVDF membrane (Millipore, Esch-
born, Germany) for 40 min at 15 V in a Semi-Dry blotting chamber
(BioRad, Mu«nchen, Germany).
2.7. Active site labelling
A⁄nity-puri¢ed PHBSP was incubated with the biotinylated serine
protease inhibitor PPACK prior to SDS-PAGE and Western blot as
described above. Inhibitor-labelled bands were visualized with extra-
vidin-peroxidase and DAB as substrate.
2.8. Amino acid sequence analysis
After SDS-PAGE proteins were transferred to a PVDF membrane
and stained with Coomassie. N-terminal amino acid sequences of the
excised blotted protein bands were analyzed by automated Edman
degradation with an Amino Acid Sequencer Procise 492 with on-
line PTH-Analyser 140C and UV detector 785A (Perkin Elmer/Ap-
plied Biosystems, Weiterstadt, Germany).
2.9. Active site titration
The number of active sites of PHBSP was determined in order to
calculate kinetic constants. Since for PHBSP no active site titrant was
available the concentration of active sites was calculated as follows:
First, the concentration of active sites of a trypsin preparation was
determined by titration with the tight binding £uorogenic substrate
HBMC in a Perkin Elmer £uorimeter LS50B (excitation: V= 365 nm;
emission: V= 445 nm). Second, a solution of aprotinin was titrated
with trypsin (100 nM ¢nal concentration) according to the tight bind-
ing theory [6,7]. Finally, from tight binding inhibition experiments
with aprotinin of known concentrations, the concentration of proteo-
lytically active PHBSP was calculated.
3. Results and discussion
3.1. Isolation of PHBSP during puri¢cation of vitamin
K-dependent coagulation factors
After binding of the plasma proteins to the anion exchanger
DEAE Sephadex A50 and rinsing of the matrix with 0.125 M
NaCl, the majority of bound proteins was eluted with bu¡er
E1 containing 0.5 M NaCl (Fig. 1A). In order to regenerate
the gel the column was subsequently washed with bu¡er E2
containing 2 M NaCl. Interestingly, a strong amidolytic ac-
tivity towards thrombin- and FXa-selective chromogenic sub-
strates was eluted during this step (Fig. 1A, B). As shown by
Table 1
Chromogenic substrate pro¢le
Substrate Selectivity Formula Relative activity (%)
Pefa-3297 APC H-D-Pyr-CHG-Arg-pNA 124
Pefa-5114 Thrombin H-D-CHG-Ala-Arg-pNAW2AcOH 114
S-2765 FXa, trypsin Z-D-Arg-Gly-Arg-pNAW2HCl 100
Pefa-5523 FXa CH3OCO-D-CHA-Gly-Arg-pNAWAcOH 98
S-2366 APC Pyr-Pro-Arg-pNAWHCl 73
Pefa-5773 APC H-D-Lys(Cbo)-Pro-Arg-pNAW2AcOH 70
S-2238 Thrombin H-D-Phe-Pip-Arg-pNAW2HCl 66
Pefa-5979 FVIIa CH3SO2-D-CHA-But-Arg-pNAWAcOH 65
Pefa-3107 FIXa CH3SO2-D-CHG-Gly-Arg-pNAWAcOH 42
Pefa-5329 Plasmin H-D-Ala-CHT-Lys-pNAW2AcOH 27
S-2222 FXa, trypsin Bz-Ile-Glu(Q-OR)-Gly-Arg-pNAWHCl 14
Substrates are listed in the order of PHBSP activity relative to S2765. (Pyr, L-pyroglutamic acid; CHG, cyclohexylglycine; CHA, cyclohexylala-
nine; CBO, benzyloxycarbonyl; CHT, cyclohexyltyrosine; Bz, benzoyl).
Fig. 1. Elution pro¢les anion exchange chromatography. A: Protein
content (by A280 ; open circles) and chromogenic activity using
S2765 (solid circles). B: Fractions containing FII were detected after
activation with ECV. The amidolytic activity is shown before (open
squares) and after (solid squares) activation using S2238. C: Detec-
tion of FX (solid triangle) and FIX (open triangle) containing frac-
tions was achieved by ELISA.
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ELISA, the vitamin K-dependent coagulation factors FIX
and FX (Fig. 1C) as well as FVII and protein C (data not
shown) were predominantly eluted with bu¡er E1. This is also
valid for FII, since incubation of prothrombin with the spe-
ci¢c activator ECV revealed the generation of thrombin activ-
ity, whereas the cleavage of the thrombin-selective substrate in
the E2 eluate was not enhanced by ECV (Fig. 1B). The latter
activity could not be inhibited by hirudin or AT III but by
aprotinin (inhibition experiments with the puri¢ed protease
are shown in Fig. 2), indicating that thrombin is not respon-
sible for the observed activity. Thus, from the elution pro¢le
and the inhibition experiments it was concluded that the ami-
dolytic activity was not caused by a protease of the coagula-
tion system.
Since aprotinin was an e¡ective inhibitor of the amidolytic
activity, aprotinin a⁄nity chromatography using Aprotinin-
Eupergit was applied for further puri¢cation of the protease.
Another aprotinin matrix, Aprotinin-Sepharose was not suit-
able, probably because of lacking a spacer. The amidolytic
activity was strongly reduced in the aprotinin column £ow-
through but could be retrieved in the eluate (data not shown).
The ¢nal yield of puri¢cation was about 1.6 mg protein/l
plasma with a speci¢c activity of 50 U/mg (substrate S2765).
SDS gel electrophoresis of the proteins obtained from each
puri¢cation step revealed the accumulation of a dominant 70
kDa band under non-reducing conditions (Fig. 3A2). Under
reducing conditions two bands of about 50 kDa and 30 kDa
were observed (Fig. 3A1) suggesting that the unknown pro-
teolytic activity is caused by the 70 kDa protein which com-
prises a two-chain, disul¢de linked molecule. Occasionally,
under reducing conditions two additional bands of 40 and
17 kDa could be observed. As shown by amino acid sequence
analysis, these additional bands were fragments of the 50 kDa
and 30 kDa polypeptide chains, respectively (Table 2). In
order to identify the active site containing chain of the mol-
ecule, the a⁄nity-puri¢ed protein was treated with the bio-
tinylated serine protease inhibitor PPACK prior to SDS gel
electrophoresis. As shown in Fig. 3B, the 70 kDa protein is
strongly labelled under non-reducing conditions, whereas
under reducing conditions the inhibitor is exclusively associ-
ated with the 30 kDa subunit. These data demonstrate that
the protein puri¢ed from plasma is an active serine protease
which consists of a heavy and a light chain covalently linked
by disul¢de bond(s) and that the proteolytic activity is located
on the light chain.
3.2. Amino acid sequence analysis
In order to unequivocally identify the enzyme N-terminal
amino acid sequence analyses of the protein bands separated
by SDS-PAGE under reducing conditions were performed
(Table 2). The 30 kDa and the 17 kDa fragments exhibited
identical N-termini. This implies that the smaller fragment is
the N-terminal part of the 30 kDa chain. The 50 kDa and the
40 kDa fragments have N-termini that are distinct from each
other. A homology search in a data bank revealed that these
sequences were not known on the level of protein sequence
analysis. However, nearly complete identity was found to the
putative amino acid sequence deduced from the hepatocyte
growth factor activator (HGFA)-like mRNA (registered in
DDBJ, accession number D49742). Only the Lys at position
6 of the 50 kDa chain is di¡erent from the predicted amino
acid Trp. In our analysis there is also a minor signal of Trp at
this position (about 10% of the signal for Lys). Furthermore,
we found two equivalent signals for Ala and Asp at position 9
of the same chain, whereas the deduced amino acid is Asp.
Whether these di¡erences are due to a sequencing error or to
an amino acid polymorphism is not yet clear. The N-terminus
of the 50 kDa fragment is located eight amino acids down-
stream of the N-terminus of the putative mature HGFA-like
protein. Whether this terminus arises from another cleavage
site of the signal peptidase or results from cleavage related to
the activation of the proenzyme or whether this terminus is
caused by partial degradation remains to be elucidated.
In 1996 the puri¢cation and characterization of a novel
hyaluronan binding protein from human plasma (PHBP)
was published, which also had identical amino acid sequences
to the putative HGFA-like protein [10]. The strategy for the
puri¢cation of PHBP revealed a protein which gave a single
70 kDa band on SDS-PAGE under non-reducing conditions,
Fig. 2. Inhibition pro¢le of puri¢ed PHBSP. Remaining PHBSP ac-
tivity was determined after 5 min incubation with hirudin (Hir, 1.35
U/ml), aprotinin (Apr, 0.8 WM), antithrombin (AT III, 5 WM), K2-
antiplasmin (a2-AP, 0.2 WM), K1-proteinase inhibitor (a1-PI, 1 WM)
and C1-esterase inhibitor (C1-Inh, 1 WM).
Fig. 3. SDS-PAGE and Western blot analysis of samples on various
steps of puri¢cation. A: Samples were run on a 12.5% gel under re-
ducing conditions (A1) or on a 10% gel under non-reducing condi-
tions (A2) and stained with Coomassie. Lane M, molecular mass
marker (175, 83, 62, 47.5, 32.5 and (only in A1) 25 kDa); lane 1,
plasma; lane 2, 0.5 M NaCl eluate of the DEAE chromatography;
lane 3, 2 M NaCl eluate; lane 4, puri¢ed PHBSP after aprotinin af-
¢nity chromatography. B: A⁄nity-puri¢ed PHBSP was labelled
with biotinylated PPACK prior to electrophoresis and transferred to
a PVDF membrane. Labelled bands were visualized with extravidin-
peroxidase. Lane S, prestained molecular mass marker (104, 82,
48.3, 33.4, 28.3, and 19.4 kDa); lane 1, reducing conditions; lane 2,
non-reducing conditions.
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and 50 kDa and 17 kDa under reducing conditions. For the
following reasons we suggest that PHBP and the protease
described here are several forms of the same precursor pro-
tein. PHBP and PHBSP have comparable features regarding
the origin from human plasma, the apparent molecular mass
under non-reducing conditions, the heterodimeric composi-
tion, the amino acid sequences, the hyaluronan binding prop-
erties (data not shown) as well as the yield of the puri¢cation.
The latter point is so far surprising as with our puri¢cation
procedure using aprotinin a⁄nity chromatography only an
active form of the enzyme was isolated, whereas the puri¢ca-
tion by hyaluronan a⁄nity chromatography should also be
capable to isolate the zymogen of the protease. The di¡erence
regarding the apparent molecular mass of the light chain can
be explained by further proteolytic degradation of the frag-
ment as was suggested by Choi-Miura et al., since the 17 kDa
fragment is much smaller than the molecular mass calculated
from the amino acid sequence [10]. We also observed a C-
terminal degradation product of the light chain with a com-
parable molecular mass during the storage of the puri¢ed
protease. This degradation is accompanied by a loss of ami-
dolytic activity. This could also be the reason for the obser-
vation that PHBP exhibits only a weak proteolytic activity
with inter-K-trypsin inhibitor as substrate [10]. Until now
the mechanism of degradation is not yet clear. Since no fur-
ther proteases than PHBSP are detectable in our preparations,
an autoproteolytic mechanism seems likely.
In consideration of the above mentioned observations we
believe that PHBP with its 17 kDa light chain is an inactive
degradation product of the protease described here. There-
fore, in order to distinguish the novel protease of this study
from PHBP and to emphasize the enzymatic activity of the
former, we called the protein plasma hyaluronan binding ser-
ine protease (PHBSP).
3.3. Substrate/inhibitor pro¢le
Substrates with selectivity for thrombin, factor Xa, Factor
VIIa and activated protein C were all hydrolyzed with a com-
parable velocity (Table 1). Kinetic analysis according to Mi-
chaelis^Menten revealed a Km of 0.58 mM for S2238, which is
in the range usually found for chromogenic substrates of ser-
ine proteases involved in blood coagulation and ¢brinolysis.
The speci¢city constant kcat/Km amounts to 125 mM31 s31.
For Pefa-3297, the substrate with the highest cleavage rate of
the substrates under investigation, a Km of 0.56 mM and a
speci¢city constant of 250 mM31 s31 was estimated.
Although the substrate speci¢city was not investigated sys-
tematically, we assume that Arg at position P1 is a better
cleavage site than Lys (Pefa-5329). Furthermore, all substrates
exhibit an uncharged amino acid residue at P2. The size of the
side chains of these amino acids appears to have no in£uence
on the reactivity (Pefa-3297, Pefa-3107). S2222 has the same
P1 and P2 residues as S2765, Pefa-5523 and Pefa-3107, but is
less reactive. This could be due to the acidic properties of the
Glu(Q-OR) (R is each 50% CH3 and H) at P3 or the Ile at P4.
PHBSP activity was strongly suppressed by a variety of
natural serine protease inhibitors, most e⁄ciently by aprotinin
and K2-antiplasmin (Fig. 2). For aprotinin, an inhibition con-
stant Ki of 0.88 nmol/l was determined in tight binding experi-
ments. C1-esterase inhibitor and K1-proteinase inhibitor also
inhibited PHBSP, but were less e¡ective, whereas AT III did
not in£uence the activity. Nevertheless, human plasma pos-
sesses a considerable inhibition capacity for PHBSP as was
demonstrated by the loss of activity after spiking of plasma
dilutions with PHBSP (data not shown).
3.4. In£uence of bivalent metal ions on PHBSP
Since many enzymes depend on bivalent cations as cofac-
tors we investigated the in£uence of eight di¡erent bivalent
metal ions onto the chromogenic activity of the protease. Fig.
4 shows that PHBSP activity was strongly enhanced by cal-
cium ions, yielding a 3.5^4-fold increase of activity when
2 mM Ca2 was present in the reaction mixture. Two other
cations, Mn2 and Mg2, showed also an activating e¡ect.
All other metal ions had a rather inhibitory e¡ect at higher
concentrations. The result of this experiment implicates the
presence of a Ca2 binding site on PHBSP. The typical cal-
cium ion binding site of vitamin K-dependent coagulation
factors, the Gla domain, is not present on PHBSP as can be
concluded from the deduced amino acid sequence of PHBP
cDNA [10]. Another Ca2 binding structure, the epidermal
growth factor (EGF) domain which is present in many extra-
cellular proteins including those of the coagulation and ¢bri-
nolytic system [11], is found in PHBSP in triplicate. However,
a proposed consensus amino acid sequence for calcium ion
binding EGF domains D/N X D/N E/Q Xm D/N Xn Y/F
(m, n : variable numbers of amino acids) [12] is not found in
any of the PHBSP EGF modules. Whether EGF domains on
PHBSP have indeed Ca2 binding properties or whether there
is a yet unknown Ca2 binding motif on PHBSP remains to
be elucidated.
3.5. Investigations on the physiological function of PHBSP
In order to investigate the in£uence of PHBSP on the he-
mostatic system we performed global clotting tests (prothrom-
bin time, activated partial thromboplastin time) and platelet
aggregation studies (¢nal PHBSP activity: 0.016^1.6 U/ml,
substrate Pefa-5114). The results of these experiments revealed
Table 2
N-terminal amino acid sequences
Peptide Sequence
p50 SLDPDKXPA(D)Q
p40 HAENPDWYYTE
p30 IYGGFKSTAG
p17 IYGGFKSTAG
Sequence analysis was performed on peptides derived from the en-
zyme by SDS-PAGE under reducing conditions.
Fig. 4. Dependence of PHBSP on divalent cations. Cations were
added as chloride salts except Co (nitrate), Cu and Fe (sulfates);
C, control.
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no hints for any e¡ect of PHBSB neither on the intrinsic or
extrinsic coagulation system nor on the platelet function.
However, another research group, which became interested
in PHBSP after presentation of our data on a scienti¢c meet-
ing [13], recently described an activation of FVII and an in-
activation of FVIII and FV by PHBSP [14]. We could con¢rm
these ¢ndings in so far as we could also demonstrate a short-
ening of the clotting time of FVII depleted plasma using the
STACLOT VIIa-rTF assay (Roche Diagnostics, Mannheim,
Germany) after addition of a partially puri¢ed FVII concen-
trate, which was preincubated with PHBSP compared to con-
trol experiments without PHBSP or after inactivation of
PHBSP by aprotinin. Furthermore, besides the possible pro-
and anticoagulatory properties a pro¢brinolytic activity of
PHBSP by activating single chain plasminogen activators
was described [15].
Nevertheless, the physiological relevance of these ¢ndings
remains to be clari¢ed. Taking the strong inhibitory properties
of human plasma into consideration it is of primary interest to
evaluate whether PHBSP exhibits the functions described
above also in vivo. Thus, further work is needed to elucidate
the role of PHBSP in the hemostatic system.
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